Search results
Results from the WOW.Com Content Network
One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 ...
As people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections.
Moderna cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine.The company now expects $1.5 to $2 billion in revenue ...
COVID-19 vaccines gave Moderna, Pfizer and Johnson & Johnson a boost — but are their stocks still good buys in 2021? Here's what to consider before investing.
As a result, share prices have fallen and the stock trades near its lowest level in years. The falling share price has pushed the stock's dividend yield to nearly 6%. ... Pfizer's vaccine ...
Moderna stock fell over 9% on ... development of a COVID-19 vaccine fueled a massive surge in revenue — rising more than 2,000% in 2021 from the prior year, with the vaccine maker turning its ...
Like a fad that arrived and left, Covid-19 vaccine stocks are out of favor now. Novavax (NASDAQ:NVAX) is facing tremendous selling pressure compared to its peers. Unlike its competitors that ...
As the omicron variant picks up speed, investors are turning to vaccine stocks that could potentially profit. The U.S. is currently averaging 121,107 new Covid-19 cases per day and showing no ...